JP7546582B2 - 治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法 - Google Patents

治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法 Download PDF

Info

Publication number
JP7546582B2
JP7546582B2 JP2021549565A JP2021549565A JP7546582B2 JP 7546582 B2 JP7546582 B2 JP 7546582B2 JP 2021549565 A JP2021549565 A JP 2021549565A JP 2021549565 A JP2021549565 A JP 2021549565A JP 7546582 B2 JP7546582 B2 JP 7546582B2
Authority
JP
Japan
Prior art keywords
cells
gamma delta
cell
cell population
delta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021549565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521027A (ja
JP2022521027A5 (enExample
Inventor
トニー ペレド
Original Assignee
ガミダ セル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ガミダ セル リミテッド filed Critical ガミダ セル リミテッド
Publication of JP2022521027A publication Critical patent/JP2022521027A/ja
Publication of JP2022521027A5 publication Critical patent/JP2022521027A5/ja
Priority to JP2024060371A priority Critical patent/JP2024088717A/ja
Application granted granted Critical
Publication of JP7546582B2 publication Critical patent/JP7546582B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021549565A 2019-02-24 2020-02-24 治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法 Active JP7546582B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024060371A JP2024088717A (ja) 2019-02-24 2024-04-03 治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962809671P 2019-02-24 2019-02-24
US62/809,671 2019-02-24
PCT/IL2020/050206 WO2020170260A1 (en) 2019-02-24 2020-02-24 Method of homing and retention of gammadelta t cells for generating cell compositions for use in therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024060371A Division JP2024088717A (ja) 2019-02-24 2024-04-03 治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法

Publications (3)

Publication Number Publication Date
JP2022521027A JP2022521027A (ja) 2022-04-04
JP2022521027A5 JP2022521027A5 (enExample) 2023-03-03
JP7546582B2 true JP7546582B2 (ja) 2024-09-06

Family

ID=72143612

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021549565A Active JP7546582B2 (ja) 2019-02-24 2020-02-24 治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法
JP2024060371A Pending JP2024088717A (ja) 2019-02-24 2024-04-03 治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024060371A Pending JP2024088717A (ja) 2019-02-24 2024-04-03 治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法

Country Status (11)

Country Link
US (1) US20220143086A1 (enExample)
EP (1) EP3927353A4 (enExample)
JP (2) JP7546582B2 (enExample)
KR (1) KR20210133996A (enExample)
CN (1) CN113710257A (enExample)
AU (1) AU2020225597A1 (enExample)
BR (1) BR112021016698A2 (enExample)
CA (1) CA3130442A1 (enExample)
IL (1) IL285806B2 (enExample)
SG (1) SG11202109055UA (enExample)
WO (1) WO2020170260A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024088717A (ja) * 2019-02-24 2024-07-02 ガミダ セル リミテッド 治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023069322A1 (en) * 2021-10-20 2023-04-27 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Methods and materials for expanding tumor infiltrating gamma-delta t cells
AU2024210701A1 (en) * 2023-01-17 2025-07-31 Ansun Biopharma, Inc. Methods of producing gamma delta t cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515497A (ja) 2009-12-29 2013-05-09 ガミダ セル リミテッド ナチュラルキラー細胞の増殖および活性の強化方法
JP2016539929A (ja) 2013-10-25 2016-12-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのポリクローナルγδＴ細胞

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846393B2 (en) * 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
CN102154205A (zh) * 2011-01-31 2011-08-17 郑骏年 高纯度、高细胞毒活性的γδT细胞的制备方法
RU2756247C2 (ru) * 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
KR102929174B1 (ko) * 2015-10-30 2026-02-20 더 리전츠 오브 더 유니버시티 오브 캘리포니아 줄기세포로부터 t-세포를 생산하는 방법 및 상기 t-세포를 이용한 면역치료 방법
JP7212615B2 (ja) * 2016-10-05 2023-01-25 フジフィルム セルラー ダイナミクス，インコーポレイテッド 多能性幹細胞からｈｌａホモ接合免疫細胞への指向分化方法
US10731128B2 (en) * 2016-11-22 2020-08-04 Alloplex Biotherapeutics, Inc. Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
US12440578B2 (en) * 2017-02-22 2025-10-14 Io Biosciences, Inc. Nucleic acid constructs comprising gene editing multi-sites and uses thereof
CN107164322A (zh) * 2017-07-05 2017-09-15 泰山医学院附属医院 一种用于人γδT细胞扩增的培养基及其制备方法
CN108949685B (zh) * 2018-08-02 2022-03-29 吉林大学第一医院 一种体外诱导扩增高杀伤活性γδT细胞的方法
EP3927353A4 (en) * 2019-02-24 2022-11-23 Gamida-Cell Ltd. METHOD OF ECOTAXY AND RETENTION OF GAMMADELTA T LYMPHOCYTES, OPTIONALLY WITH NATURAL KILLER CELLS, ALLOWING THE GENERATION OF CELLULAR COMPOSITIONS FOR USE IN THERAPY

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013515497A (ja) 2009-12-29 2013-05-09 ガミダ セル リミテッド ナチュラルキラー細胞の増殖および活性の強化方法
JP2016539929A (ja) 2013-10-25 2016-12-22 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのポリクローナルγδＴ細胞

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EBioMedicine，2018年12月07日，Vol.39，pp.44-58
Experimental Hematology，2012年，Vol.40，pp.342-355
Microbes and Infection，2005年，Vol.7，pp.510-517

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024088717A (ja) * 2019-02-24 2024-07-02 ガミダ セル リミテッド 治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法

Also Published As

Publication number Publication date
US20220143086A1 (en) 2022-05-12
IL285806B2 (en) 2025-05-01
WO2020170260A1 (en) 2020-08-27
JP2022521027A (ja) 2022-04-04
AU2020225597A1 (en) 2021-10-07
KR20210133996A (ko) 2021-11-08
IL285806A (en) 2021-10-31
SG11202109055UA (en) 2021-09-29
EP3927353A1 (en) 2021-12-29
IL285806B1 (en) 2025-01-01
EP3927353A4 (en) 2022-11-23
CA3130442A1 (en) 2020-08-27
CN113710257A (zh) 2021-11-26
BR112021016698A2 (pt) 2021-10-13
JP2024088717A (ja) 2024-07-02

Similar Documents

Publication Publication Date Title
JP6215394B2 (ja) エクスビボ培養されたナチュラルキラー細胞の集団
JP2024088717A (ja) 治療に使用する細胞組成物を生成するためのガンマ・デルタｔ細胞のホーミング及び保持の方法
JP5906168B2 (ja) 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法
JP2025156345A (ja) 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法
Min et al. Optimization of large-scale expansion and cryopreservation of human natural killer cells for anti-tumor therapy
JP7239567B2 (ja) Ｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用
JP2005536982A (ja) インビトロにおけるｔ細胞増幅および増幅されたｔ細胞集団
Ghorai et al. Current strategies to improve chimeric antigen receptor T (CAR-T) cell persistence
Ding et al. Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma
Zhang et al. Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood
JP2025072546A (ja) 血液疾患を治療するためのキット
WO2018234421A1 (en) METHOD FOR MODULATING IMMUNE CELLS
JP2021516666A (ja) 前立腺がん特異的髄浸潤リンパ球およびその使用
JP2022529536A (ja) 悪性および非悪性血液疾患の治療のための免疫枯渇の組成物および方法
JP2023505192A (ja) 養子細胞療法としての遺伝子操作された二重陰性ｔ細胞
JP2024526837A (ja) 治療用ｎｋ細胞集団
BR112019024113A2 (pt) Métodos para selecionar uma unidade de sangue do cordão umbilical e frações de célula sanguínea do cordão umbilical e para preparar uma unidade de sangue do cordão umbilical.
HK40062462A (en) Method of homing and retention of gammadelta t cells, optionally using natural killer cells, for generating cell compositions for use in therapy
JP2022552819A (ja) 遺伝子改変自己ｔ細胞免疫療法を使用する治療方法
BR112019024077A2 (pt) Métodos para selecionar uma unidade de sangue do cordão umbilical criopreservada para transplantação e expansão ex-vivo e para preparar uma única unidade de sangue do cordão umbilical, e, artigo de fabricação.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240827

R150 Certificate of patent or registration of utility model

Ref document number: 7546582

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150